Our Medical Affairs team is a peer-based resource for healthcare providers. We are committed to advancing science and medicine through awareness, education, and research.
Find your SMA using the map
Michael Breen, OD
15440 Laguna Canyon Road,
Suite 150
Irvine, CA 92618
Find your SMA using the map
Find your SMA using the map
Find your SMA using the map
Find your SMA using the map
Find your SMA using the map
Find your SMA using the map
Find your SMA using the map
Find your SMA using the map
Find your SMA using the map
Find your SMA using the map
As part of our commitment to advancing science and medicine, Tarsus believes in supporting independent and ethical clinical research, designed and conducted by qualified third-party investigators.
Clinical study proposals must offer new and meaningful scientific evidence and qualify for institutional review board (IRB) approval.
Qualified investigators can submit an unsolicited research abstract aligned with the following strategic areas of interest using this short request form.
Strategic areas of interest:
To be considered for review, the proposal must include study objectives, end points, hypotheses, and a short abstract.
For more information about our Investigator-Initiated Trial program, please contact your Senior Medical Ambassador.
Tarsus recognizes the importance of independent medical education and provides financial support for accredited and nonaccredited professional education for US healthcare providers. It is important to note that Tarsus does not assume responsibility for the following:
To submit a grant request, please complete the form or upload a file detailing the date(s), location(s), proposed audience, format/activity, educational objectives, and budget requested.
Please ensure that your organization can be classified as one of the following:
Tarsus is currently considering support of independent medical education programs that focus on Demodex blepharitis.
Tarsus is committed to providing high-quality and consistent medical information. We recognize the importance of having access to trusted, accurate, and balanced clinical and scientific information about our investigational products.
Use this form to contact the Medical Affairs team with any questions you may have.
Explore Tarsus-supported works by using this repository of publications and conference materials
TP-03 (lotilaner ophthalmic solution, 0.25%) is an investigational product that is not FDA approved. Safety and efficacy have not been established by health authorities.
NATURE
March 2023
Abstract
Purpose: Twelve ocular surface disease experts convened to achieve consensus about Demodex blepharitis (DB) using a modified Delphi panel process.
CLINICAL OPHTHALMOLOGY
February 2023
Abstract
Purpose: To obtain consensus on Demodex blepharitis (DB) treatment using a modified Delphi panel process.
Clinical Ophthalmology
September 2022
Abstract
Purpose: To evaluate the impact of Demodex blepharitis on patients’ daily activities and quality of life.
Ocular Immunology and Inflammation
August 2022
Abstract
Purpose: To evaluate the efficacy and safety of lotilaner ophthalmic solution, 0.25% eyedrops compared to vehicle for the treatment of Demodex blepharitis.
Cornea
May 2022
Abstract
Purpose: The purpose of this study was to evaluate the safety and efficacy of lotilaner ophthalmic solution, 0.25%, compared with vehicle for the treatment of Demodex blepharitis.
Clinical Ophthalmology
April 2022
Abstract
Purpose: To evaluate the prevalence of Demodex blepharitis by its pathognomonic sign, collarettes, in patients presenting for any reason to eye care clinics in the United States.
Journal of Ophthalmology
September 2021
Abstract
Purpose: To evaluate safety and efficacy of topical lotilaner ophthalmic solution, 0.25% for the treatment of Demodex blepharitis.
Contact Lens & Anterior Eye
August 2021
Abstract
Purpose: To evaluate the safety and efficacy of lotilaner ophthalmic solution, 0.25% for the treatment of blepharitis due to Demodex infestation compared to vehicle control.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
January 2021
Abstract
Purpose: To evaluate the efficacy of topical lotilaner ophthalmic solution, 0.25%, in patients with Demodex blepharitis.
PRESENTED AT WCC 2022
September 2022
Abstract
Purpose: To evaluate the safety and efficacy of lotilaner ophthalmic solution, 0.25% (TP-03, Tarsus Pharmaceuticals) for the treatment of Demodex blepharitis (DB).
PRESENTED AT WCC 2022
September 2022
Abstract
Purpose: To evaluate the long-term efficacy and safety of lotilaner ophthalmic solution, 0.25% (TP-03, Tarsus Pharmaceuticals) after the completion of a 6-week treatment for Demodex blepharitis.
Presented at ARVO 2022
August 2022
Abstract
Purpose: Further evaluate the clinical impact of Demodex blepharitis.
PRESENTED AT ASCRS 2022
April 2022
Abstract
Purpose: Evaluate the bacterial composition on the eyelid margin of patients with and without collarettes.